Targeted therapy may delay end-of-life transition, study finds

12/6/2012 | MedWire News (U.K.)

Targeted therapies such as bevacizumab, erlotinib, sorafenib and rituximab are increasingly are used in advanced cancer patients at the end of life, according to research from the University of Texas MD Anderson Cancer Center. The study team wrote in the Journal of Pain and Symptom Management these treatments are used about as often as chemotherapy and could delay a transition in care, "diverting patients' precious time and energy to the pursuit of cancer treatments rather than planning ahead."

View Full Article in:

MedWire News (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI
Senior Vice-President Managed Care Mid-Atlantic Region
Mercy Health System
Conshohocken, PA
Associate Chief Financial Officer
Commonwealth Care Alliance
Boston, MA